Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710899 | 0.78 | OPRK1 (0.34) | OPRK1 | |
| SCHEMBL16120530 | 0.77 | NCF1 (0.33) | NCF1 | |
| SCHEMBL6628398 | 0.75 | EPHX2 (0.33) | NCF1 | |
| SCHEMBL6274327 | 0.75 | NCF1 (0.32) | NCF1 | |
| SCHEMBL1424113 | 0.75 | NCF1 (0.52) | NCF1 | |
| SCHEMBL22930835 | 0.73 | HRH3 (0.32) | DPP4NCF1 | |
| SCHEMBL5901179 | 0.72 | BRD4 (0.35) | DPP4NCF1 | |
| SCHEMBL8744486 | 0.72 | NCF1 (0.39) | NCF1 | |
| SCHEMBL102076 | 0.72 | NCF1 (0.52) | OPRK1NCF1 | |
| SCHEMBL21781829 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-10968205-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968205-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | OPRK1 1373/4885DPP4 787/4885NCF1 1469/4885 |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | OPRK1 1388/4885DPP4 1156/4885NCF1 1550/4885 |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | OPRK1 1373/4885DPP4 787/4885NCF1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.